ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 8 (3) 237-248    DOI: 10.1677/erc.0.0080237
Copyright © 2001 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (65)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stein, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stein, R.
Endocrine Related Cancer, Vol 8, Issue 3, 237-248
Copyright © 2001 by Society for Endocrinology


Articles

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

RC Stein


The phosphoinositide 3-kinases (PI3-kinases) are a family of lipid kinases that have a key role in the regulation of many cellular processes including proliferation, survival, carbohydrate metabolism, and motility. There is now strong evidence that some members of the PI3-kinase family have an important role in cancer. Emerging evidence for functional specialisation of PI3-kinase isoforms suggests that isoform selective inhibitors, in contrast to the existing non-selective inhibitors wortmannin and LY294002, may prove to be useful anticancer drugs.


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S.-M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, et al.
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Mol. Cancer Ther., July 1, 2008; 7(7): 1851 - 1863.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. Maddika, S. R. Ande, E. Wiechec, L. L. Hansen, S. Wesselborg, and M. Los
Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis
J. Cell Sci., April 1, 2008; 121(7): 979 - 988.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Cao, L. Liu, W. Packwood, M. Merkel, P. D. Hurn, and D. M. Van Winkle
Sex differences in the mechanism of Met5-enkephalin-induced cardioprotection: role of PI3K/Akt
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H302 - H310.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Angelo, M. Anita, A. Amalia, and T. Stefania
Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?
Clin. Cancer Res., October 15, 2007; 13(20): 5988 - 5990.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. K. Bowers, P. Marder, L. J. Green, C. L. Horn, A. L. Faber, and J. E. Thomas
A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy
Mol. Cancer Ther., September 1, 2007; 6(9): 2600 - 2607.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
P. Bertino, C. Porta, D. Barbone, S. Germano, S. Busacca, S. Pinato, G. Tassi, R. Favoni, G. Gaudino, and L. Mutti
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
Thorax, August 1, 2007; 62(8): 690 - 695.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. A. Engelman
The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4637s - 4640s.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. A. Bradley, M. G. Clark, and S. Rattigan
Acute effects of wortmannin on insulin's hemodynamic and metabolic actions in vivo
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E779 - E787.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Y. Zhang, A. M. Ahmed, N. McFarlane, C. Capone, D. R. Boreham, R. Truant, S. A. Igdoura, and B. L. Trigatti
Regulation of SR-BI-mediated selective lipid uptake in Chinese hamster ovary-derived cells by protein kinase signaling pathways
J. Lipid Res., February 1, 2007; 48(2): 405 - 416.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. Chaudhuri, S. Orsulic, and B. T. Ashok
Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 334 - 345.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M.-R. Blanchet, E. Israel-Assayag, P. Daleau, M.-J. Beaulieu, and Y. Cormier
Dimethyphenylpiperazinium, a nicotinic receptor agonist, downregulates inflammation in monocytes/macrophages through PI3K and PLC chronic activation
Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L757 - L763.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
X.-B. Liang, L.-J. Ma, T. Naito, Y. Wang, M. Madaio, R. Zent, A. Pozzi, and A. B. Fogo
Angiotensin Type 1 Receptor Blocker Restores Podocyte Potential to Promote Glomerular Endothelial Cell Growth
J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1886 - 1895.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Maffucci, E. Piccolo, A. Cumashi, M. Iezzi, A. M. Riley, A. Saiardi, H. Y. Godage, C. Rossi, M. Broggini, S. Iacobelli, et al.
Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects
Cancer Res., September 15, 2005; 65(18): 8339 - 8349.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Cacciotti, D. Barbone, C. Porta, D. A. Altomare, J. R. Testa, L. Mutti, and G. Gaudino
SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure
Cancer Res., June 15, 2005; 65(12): 5256 - 5262.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
B. K. Lundholt, V. Linde, F. Loechel, H.-C. Pedersen, S. Moller, M. Praestegaard, I. Mikkelsen, K. Scudder, S. P. Bjorn, M. Heide, et al.
Identification of Akt Pathway Inhibitors Using Redistribution Screening on the FLIPR and the IN Cell 3000 Analyzer
J Biomol Screen, February 1, 2005; 10(1): 20 - 29.
[Abstract] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. T. Ihle, R. Williams, S. Chow, W. Chew, M. I. Berggren, G. Paine-Murrieta, D. J. Minion, R. J. Halter, P. Wipf, R. Abraham, et al.
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling
Mol. Cancer Ther., July 1, 2004; 3(7): 763 - 772.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. L. Holleran, J. Fourcade, M. J. Egorin, J. L. Eiseman, R. A. Parise, S. M. Musser, K. D. White, J. M. Covey, G. L. Forrest, and S.-S. Pan
IN VITRO METABOLISM OF THE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR, WORTMANNIN, BY CARBONYL REDUCTASE
Drug Metab. Dispos., May 1, 2004; 32(5): 490 - 496.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. L. Williams, C. Li, T. Ha, T. Ozment-Skelton, J. H. Kalbfleisch, J. Preiszner, L. Brooks, K. Breuel, and J. B. Schweitzer
Modulation of the Phosphoinositide 3-Kinase Pathway Alters Innate Resistance to Polymicrobial Sepsis
J. Immunol., January 1, 2004; 172(1): 449 - 456.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
V. M. Bondar, B. Sweeney-Gotsch, M. Andreeff, G. B. Mills, and D. J. McConkey
Inhibition of the Phosphatidylinositol 3'-Kinase-AKT Pathway Induces Apoptosis in Pancreatic Carcinoma Cells in Vitro and in Vivo
Mol. Cancer Ther., October 1, 2002; 1(12): 989 - 997.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
C. B. Knobbe, A. Merlo, and G. Reifenberger
Pten signaling in gliomas
Neuro-oncol, July 1, 2002; 4(3): 196 - 211.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society for Endocrinology.